Equities

Pulike Biological Engineering Inc

603566:SHH

Pulike Biological Engineering Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.08
  • Today's Change-0.11 / -0.98%
  • Shares traded1.92m
  • 1 Year change-48.68%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments719963240
Total Receivables, Net490507310
Total Inventory184192171
Prepaid expenses11129.18
Other current assets, total5.44104.46
Total current assets1,4091,683733
Property, plant & equipment, net1,175950652
Goodwill, net181818
Intangibles, net283286276
Long term investments340383418
Note receivable - long term------
Other long term assets------
Total assets3,2623,3962,168
LIABILITIES
Accounts payable11012349
Accrued expenses697060
Notes payable/short-term debt35550
Current portion long-term debt/capital leases1.000.81--
Other current liabilities, total294307237
Total current liabilities508556346
Total long term debt1.061.870
Total debt37580
Deferred income tax7.652515
Minority interest------
Other liabilities, total228.266.97
Total liabilities538592368
SHAREHOLDERS EQUITY
Common stock353353321
Additional paid-in capital1,3241,346473
Retained earnings (accumulated deficit)1,1881,2391,139
Treasury stock - common(141)(134)(134)
Unrealized gain (loss)------
Other equity, total------
Total equity2,7242,8041,800
Total liabilities & shareholders' equity3,2623,3962,168
Total common shares outstanding346346315
Treasury shares - common primary issue7.216.856.85
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.